VivoSeq
Oncology

Rare Tumor

0

Pipeline Programs↗

3

Active Trials↗

1

Companies Involved↗

Rare Tumor is an early-stage landscape with 0 programs across 1 company. The most active players are Novartis.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

5

clinical trials

Terminated1 · 20%
Completed1 · 20%
Recruiting1 · 20%
Active, not recruiting1 · 20%
Not yet recruiting1 · 20%

Clinical Trials

Trial Activity

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
Terminated·Novartis logoNovartis·Phase 2·NCT00958841·118 enrolled
Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03108131·49 enrolled
PLATFORM Study of Precision Medicine for Rare Tumors
Recruiting·—·Phase 2·NCT04423185·770 enrolled
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT02834013·818 enrolled
Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)
Not yet recruiting·—·Phase 1/2·NCT07307053·600 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)